Committee opinion: number 262, December 2001. Risk of breast cancer with estrogen-progestin replacement therapy.
Recent articles have examined the association between the use of combination estrogen-progestin regimens for hormone replacement therapy (HRT) and the risk of breast cancer. The objective of this Committee Opinion is to evaluate critically the presented evidence. Although epidemiologic studies suggest that the addition of progestin to estrogens may increase the risk of breast cancer, this increased risk has not been proved. The American College of Obstetricians and Gynecologists continues to recommend that HRT be considered as a treatment to relieve vasomotor symptoms and genitourinary tract atrophy and to reduce the risks and benefits of HRT. When considering the use of HRT for longer than 5 years, the clinician and individual patient should weigh the benefits versus the potential side effects and risks for that particular patient.
D001943:Breast Neoplasms / Q000139:chemically induced*; D015331:Cohort Studies; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D011372:Progestins / Q000009:adverse effects; D012307:Risk Factors
D004967:Estrogens; D011372:Progestins